GlassScriptPhysician profile
Beverly Wang
NPI 1902571805
$10,348.59
in general payments reported to CMS, 2019-2025
59 companies · $3,767 in 2025
The $3,767 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.14 · 2022: $1,156 · 2023: $2,274 · 2024: $3,128 · 2025: $3,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,106 · Education: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,106.22 |
| Education | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,557.70 | 2022-2025 | |
| Emd Serono, INC. | $1,339.54 | 2023-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $888.30 | 2023-2025 | Xcopri |
| Lundbeck LLC | $627.89 | 2023-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $524.84 | 2021-2023 | Xifaxan |
| Biogen, INC. | $472.42 | 2023-2025 | Tysabri, Vumerity, Plegridy |
| Celgene Corporation | $440.75 | 2022-2025 | Zeposia |
| Eisai INC. | $372.40 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $297.52 | 2023-2025 | Ultomiris |
| Pfizer INC. | $279.61 | 2023-2025 | |
| Genzyme Corporation | $259.43 | 2022-2025 | |
| Tg Therapeutics, INC. | $219.70 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $213.00 | 2023-2025 | Acthar |
| Genentech USA, INC. | $184.25 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Csl Behring | $171.59 | 2023-2025 | Hizentra |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $142.36 | 2022-2023 | Gattex, Entyvio |
| Averitas Pharma INC. | $129.71 | 2023-2025 | Qutenza |
| Ani Pharmaceuticals, INC. | $128.84 | 2023-2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $123.22 | 2023-2025 | Onpattro, Givlaari |
| Ucb, INC. | $115.22 | 2023-2025 | Zilbrysq, Briviact |
| Catalyst Pharmaceuticals, INC. | $110.81 | 2024-2025 | |
| Lilly USA, LLC | $109.22 | 2023-2025 | Kisunla, Amyvid |
| Otsuka America Pharmaceutical, INC. | $107.51 | 2023-2024 | Rexulti, Nuedexta |
| Janssen Biotech, INC. | $103.84 | 2022-2023 | Stelara |
| Amgen INC. | $87.78 | 2022-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $82.85 | 2024-2025 | |
| Qol Medical, LLC | $76.22 | 2022-2023 | Sucraid |
| Xeris Pharmaceuticals, INC. | $73.76 | 2024-2025 | Keveyis |
| Cycle Pharmaceuticals INC | $71.56 | 2024-2025 | Tascenso Odt, Bafiertam, Ormalvi |
| Teva Pharmaceuticals USA, INC. | $65.87 | 2024-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $65.33 | 2024-2025 | Wainua |
| Vanda Pharmaceuticals INC. | $63.60 | 2024-2025 | Ponvory |
| Kedrion Biopharma, INC. | $62.86 | 2024-2025 | Gammaked, Kedrab, Koate |
| Argenx US, INC. | $53.74 | 2025 | Vyvgart Hytrulo |
| Kyowa Kirin, INC. | $51.93 | 2024 | Nourianz |
| Ferring Pharmaceuticals INC. | $48.03 | 2022-2023 | Rebyota |
| Octapharma USA, INC. | $45.66 | 2025 | Panzyga |
| Grifols USA, LLC | $39.46 | 2025 | Gamunex-C |
| Ipsen Biopharmaceuticals, INC | $37.22 | 2025 | Dysport |
| Regeneron Healthcare Solutions, INC. | $36.58 | 2023 | Dupixent |
| Medtronic, INC. | $36.39 | 2023 | Intellis Adaptivestim |
| Tanabe Pharma America, INC. | $35.54 | 2025 | Radicava |
| Tersera Therapeutics LLC | $33.43 | 2025 | Quzyttir |
| Genentech, INC. | $31.57 | 2025 | Ocrevus |
| Boston Scientific Corporation | $29.96 | 2022 | |
| Neurelis, INC. | $28.49 | 2024-2025 | Valtoco |
| Braintree Laboratories, INC. | $27.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $26.61 | 2022 | |
| Cala Health, INC. | $25.38 | 2025 | Cala Kiq |
| Livanova USA, INC. | $24.77 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Invivyd INC | $24.19 | 2025 | Pemgarda |
| Insightec,INC | $23.78 | 2024 | Exablate |
| Amylyx Pharmaceuticals, INC. | $23.59 | 2024 | Relyvrio |
| Axsome Therapeutics, INC. | $18.22 | 2023 | Sunosi |
| Organon LLC | $17.83 | 2023 | Renflexis |
| Ultragenyx Pharmaceutical INC. | $16.84 | 2022 | |
| Acadia Pharmaceuticals INC | $16.02 | 2024 | Daybue |
| Mylan Specialty L.P. | $14.40 | 2024 | Glatiramer Acetate |
| Life Molecular Imaging LTD | $11.77 | 2024 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.